Researchers have discovered a novel method to enhance the brain’s immune response and diminish abnormal nerve-cell activity associated with Alzheimer’s disease. This study, led by Professor Minah Suh of Sungkyunkwan University, in partnership with IMNEWRUN and Professor Ho-Keun Kwon’s team at Yonsei University College of Medicine, targeted the brain’s immune cells, known as microglia. These cells typically serve as the brain’s primary defense, identifying damage and maintaining a healthy environment. However, in Alzheimer’s, this response is compromised, leading to excessive nerve-cell activity.
The study, published in Science Advances, demonstrated that two immune-regulating proteins, PD-1 and PD-L1, are altered in the brain of an Alzheimer’s model. Researchers found increased PD-1 in microglia and elevated PD-L1 in astrocytes within these models. These proteins are integral to immune responses within the brain. Through advanced microscopy, researchers observed the effects of blocking PD-L1 directly in the brains of Alzheimer’s model mice. The treatment reinstated microglial function and reduced excessive neuronal activity.
Dr. John Showalter of Linus Health, although not a participant in the study, commented on the growing body of evidence supporting the immune system’s role in Alzheimer’s and dementia. Notably, individuals vaccinated against shingles appear less prone to developing dementia. Showalter highlighted that targeting microglia could be pivotal in overhauling treatment methods, prompting further immune-mediated research.
Importantly, altering PD-L1 directly in the brain displayed a stronger effect compared to systemic antibody administration. These findings hint that disrupted immune signaling may underpin the brain’s impaired response to damage and hyperactivity in neurons. Researchers suggest that improper immune regulation restricts microglia from functioning optimally, fostering an unhealthy brain environment.
The study aligns with recent trends in Alzheimer’s research. As Dr. Showalter mentioned, only a quarter of current clinical trials focus on anti-amyloid and anti-tau drugs. Instead, 18% target inflammatory responses and immune-modifying therapies, indicating a diverse approach to treating Alzheimer’s and cognitive decline.
Despite these promising findings, translating them into human treatment remains challenging. The study, conducted in mice with an Alzheimer’s-like condition, does not confirm that blocking PD-L1 is a viable treatment for Alzheimer’s in humans. One significant barrier is the delivery method of the antibodies, which presents risks when administered directly into brain or spinal fluid. Further investigation must be undertaken to confirm these effects in humans.
“The biggest challenges found in this study are about the ability to administer the antibodies like a medication,” remarked Showalter, noting the inherent risks.
The research by Taeyoung Park et al., titled “Targeting glial PD-1/PD-L1 restores microglial homeostasis and reduces neuronal hyperactivity in an Alzheimer’s disease model,” provides crucial insights. It highlights a potential pathway to remedy the disrupted immune function observed in Alzheimer’s.